ArticleChemistry & biodiversity2026
Design, Synthesis, and Evaluation of New 1,4-Naphthoquinone-1,2,3-triazoles as Antimalarial Agents.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing resistance to existing antimalarial agents has prompted researchers to develop new therapeutic candidates. To address this, the hybridization of 1,4-naphthoquinone and 1,2,3-triazole yielded a new series of compounds evaluated as prospective in vitro antimalarial agents against the chloroquine-sensitive 3D7 and chloroquine-resistant K1 strains of Plasmodium falciparum. The target compounds were synthesized efficiently via a multistep route, involving the reaction of 1,4-naphthoquinone and p-aminobenzoic acid, followed by reactions with propargylamine and different prepared chlorides. The synthetic route was concluded using a copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) "click" reaction. Based on structure-activity relationships (SAR), the compound bearing a 4-chloroaryl moiety (9g) was the most active against P. falciparum 3D7, exhibiting 60.00% growth inhibition at 25 µM. Furthermore, compound 9k bearing a 2-methylaryl moiety exhibited the most potent activity against P. falciparum K1, showing 64.52% growth inhibition at 50 µM. In silico simulations of compound 9g on thirteen protein targets in P. falciparum indicated strong interactions with the 1J3 and 1LDG targets. Also, the stability of the ligand-protein complexes was verified for 3FGO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.